

Supplemental Data Figure Legends

Supplemental Figure 1: Immune cell populations in wild type versus SXR KO animals as described in percent of total cells in the spleen.

Supplemental Figure 2: Total yield of cells recovered via unchallenged peritoneal lavage from wild type and SXR KO animals. Mean is indicated.

Supplemental Figure 3: Surface staining of lymphoma tumor cells purified from SXR KO animals.

Supplemental Figure 4: The V_HDJ_H region was amplified, cloned, and sequenced; aligned sequence homology is indicated by geneological tree to show sequence clonality; bottom left of the geneological tree represents sequences found to be clonal during alignment.

Supplemental Figure 5: Serum gamma globulins and serum IgM in WT and SXR KO animals. Mean is indicated.

Supplemental Figure 6: Quantitative Real-Time PCR of SXR KO spleen following 3 day PCN treatment. All values are expressed as fold of DMSO.

Supplemental Figure 7: Quantitative Real-Time PCR of SXR KO lymphocytes following 24 hour treatment with NF-kB inhibitor CAPE. All values are expressed as fold of DMSO.


Supplemental Figure 8: Quantification of total percents of splenocytes from young WT or SXR KO animals cultured for 48hr hours with increasing concentrations of LPS. Percent of total splenocytes positive for both surface IgM as well as BrdU incorporation was measured by flow cytometry and was quantitated.

Supplemental Figure 9: Quantitative Real-Time PCR of spleen tissue of WT and SXR KO mice. Mean is indicated.

Supplemental Figure 10: IgM+ staining as measured by flow cytometry on cells that were depleted for CD90.2 and enriched for CD5 using magnetic beads.


Supplemental Table 1: Primer sequences used for quantitative real time PCR.

Supplemental Figure 1



Supplemental Figure 2


Peritoneal Lavage Yield



Supplemental Figure 3


Marker	Expression in SXR KO Tumor Cells
CD5	++
IgM	+++
IgD	—
B220	+ / ++
CD21	++
CD38	++

Supplemental Figure 4




Supplemental Figure 5

a




b




Supplemental Figure 6


3 Day PCN Treatment: 10mg/kg



Supplemental Figure 7




Supplemental Figure 8




Supplemental Figure 9


a




b




c



d



Supplemental Figure 10



Supplemental Table 1: Primer Sequences

Gene	Forward Primer	Reverse Primer
BAD	GGCTTGAGGAAGTCCGATCC	TGCATGATGACTGTTGGTGGC
bcl-xL	GGTGGTCATTCAGATAGG	GGTGGTCATTCAGATAGG
COX-2	TGAGCAACTATTCCAAACCAGC	GCACGTAGTCTTCGATCACTATC
c-jun	GCCAACCTCAGCAACTTC	GCTTCCTCTCTGCCTTGA
c-myb	ATTGTGGACCAGACCAGACC	GCTGGTGAGGCACTTTCTTC
GAPDH	AGGTCGGTGTGAACGGATTTG	TGTAGACCATGTAGTTGAGGTCA
IL-5	CTCTGTTGACAAGCAATGAGACG	TCTTCAGTATGTCTAGCCCCTG
IL-7	GCGGACGATCACTCCTTCTG	AGCCCCACATATTTGAAATTCCA
IL-9	ATGTTGGTGACATACATCCTTGC	TGACGGTGGATCATCCTTCAG
Lck	CCAGCTCACAATGCCAGCAG	GCTCGGGGAGGGTTCATTC
PTPN6	GCAGGAGAACAACCTCGTGTC	CCCATTGTCTAGTGGGGAGA
Siglec-G	GGCTCAAGGTCAGATGGAGA	AGGCTCCAGGACCTCAGGAA
SXR	GACGCTCAGATGCAAACCTT	TGGTCCTCAATAGGCAGGTC
TNF α	CCCTCACACTCAGATCATCTTCT	GCTACGACGTGGGCTACAG
Traf-6	ATGTTGGTGACATACATCCTTGC	ATGTTGGTGACATACATCCTTGC
Zap-70	GGGGTCTTCGACTGCCTGCG	GCCTGGCTGATGATGGCCTGC